Company intelligence / Profile preview

Crescent Foundation

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Crescent Biopharma's lead program, CR-001 (PD-1 x VEGF bispecific antibody), is designed to replicate the pharmacology of ivonescimab, which demonstrated superior efficacy compared to pembrolizumab in Phase 3 trials[1]. The company anticipates dosing patients in early 2026 with proof-of-concept data expected in the second half of 2026[1].

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (exclusive partnership for CR-001 in Greater China and CR-003 ex-Greater China)

Beyond the preview

Go deeper on Crescent Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crescent Foundation.

Explore the full profile